A5035361770- CAR-T cell therapy research
- Immunotherapy and Immune Responses
- Immune Cell Function and Interaction
- Cancer Immunotherapy and Biomarkers
- Viral Infections and Vectors
- Monoclonal and Polyclonal Antibodies Research
- Mosquito-borne diseases and control
- Cancer Research and Treatments
- HIV/AIDS drug development and treatment
- Vector-borne infectious diseases
- HIV Research and Treatment
- Cytomegalovirus and herpesvirus research
Ragon Institute of MGH, MIT and Harvard
2024
The University of Texas Southwestern Medical Center
2020-2022
Southwestern Medical Center
2020-2021
A tumor-specific pro-IL-12 rejuvenated preexisting TILs to induce tumor growth delay without inducing systemic toxicity.
Abstract As a potent lymphocyte activator, interleukin-2 (IL-2) is an FDA-approved treatment for multiple metastatic cancers. However, its clinical use limited by short half-life, low potency, and severe in vivo toxicity. Current IL-2 engineering strategies exhibit evidence of peripheral cytotoxicity. Here, we address these issues prodrug (ProIL2). We mask the activity CD8 T cell-preferential mutein/Fc fusion protein with IL2 receptor beta linked to tumor-associated protease substrate....
A cancer evaluation criterion based on T cell receptors is potentially useful for noninvasive early detection.
Abstract Interleukin-2 (IL-2) is an FDA approved treatment for multiple metastatic cancers. However, while IL-2 a potent activator of CD8 and NK cells, its clinical use limited by short in vivo half-life, low potency, severe toxicity. Current strategies reducing receptor alpha binding increasing beta reduce efficacy or increase Here, we address these issues engineering novel prodrug (ProIL2). We mask the activity T cell-preferred mutein/Fc fusion protein with IL2 linked to tumor-associated...
Broadly neutralizing antibodies (bNAbs) have shown great promise for prevention and treatment of HIV infection. Breadth bNAb neutralization, measured